Alzheimer Europe (AE) continues to develop and improve its Clinical Trials Watch (CTW), an innovative online resource providing up-to-date accessible information on clinical trials currently recruiting participants in a least one European country. The service, launched in September 2016, provides information on phase II and III clinical trials that are investigating drugs for the prevention and treatment of dementia and/or Alzheimer’s disease (AD). Although some trials have been removed since they are no longer recruiting participants, new trials have also been added, resulting in 18 clinical trials currently reported in the database.
AE added seven Phase II clinical trials to the service:
-
Abvac40 study (Araclon Biotech S.L.)
-
ACI-24-1801 study (AC Immune)
-
ETHERAL study (Oryzon)
-
MAPT-CS1 study (Ionis Pharmaceuticals, Inc.)
-
RO7105705 study (Genentech, Inc.)
-
TANGO study (Biogen)
-
VALZ-Pilot study (Hugo Lovheim).
Further information about the CTW is available on: http://www.alzheimer-europe.org/Research/Clinical-Trials-Watch